Roquefort Therapeutics PLC

Initiation of coverage

12 September 2022

HYBRIDAN
YOUR PARTNER FOR GROWTH

Key Statistics:

Code	ROQ
Listing	LSE; OTCQB
Sector	Biopharma
Market cap*	£5.3m
Shares in issue*	71.9m
Current price*	7.375p
12-month high/low*	12.5p/7.375p
Free float**	52%

**Closing price on 9 September 2022. High/low based on closing prices.*
***Free float based on Hybridan estimates.*

Share Price Performance

Year to date	-30%
Past 12 months	-31%
2021	75%

Source: Alpha Terminal

Financials Y/E Dec (£)

	Sales	EBIT	Net cash
2021	917	(917,433)	899,721

Source: Company Data

As of April 30, 2022, Roquefort Therapeutics had £2.49m in cash.

Company Description

Roquefort Therapeutics is a drug and therapy discovery and development company for hard-to-treat cancers by focusing on novel targets.

Anchored on an exclusive licensing agreement with Anagenics Limited (formally known as Cellmid) for Midkine (MDK) related patents, Lyramid (100% owned by Roquefort Therapeutics) is developing MDK antibodies targeting specific tumour types and MDK inhibiting RNA therapeutics based on oligonucleotides.

Meanwhile, Roquefort is in the process of acquiring Oncogeni for its late pre-clinical programs in MK (mesodermal killer) cell therapy and siRNA targeting novel STAT-6 target in solid tumours.

HYBRIDAN LLP
Website: www.hybridan.com
1 Poultry, London, EC2R 8EJ
@HybridanLLP

Emily Liu, CFA, CAIA
Tel: 020 3764 2344
Email: Emily Liu@hybridan.com

Oncology-focused drug discovery and pre-clinical programs backed with patents

Roquefort Therapeutics is dedicated to drug/therapeutics discovery and development for hard-to-treat cancers by focusing on novel targets.

Midkine (MDK) programs supported with an extensive patent portfolio: MDK overexpression is prevalent in many solid tumours and associated with metastasis, resistance to treatment and poor prognosis. Lyramid, acquired in December 2021, has two Midkine (MDK) programs: (1) antibodies to target specific tumour types; (2) MDK inhibiting RNA therapeutics with oligonucleotides. Lyramid's research is anchored on 10+ years of knowhow and protected by the patents exclusively licensed from Anagenics Limited (formerly known as Cellmid). Roquefort has also been applying for patents for Lyramid's own programs.

Oncogeni: Roquefort has proposed to acquire 100% of Oncogeni, spun-out from Celixir PLC in 2019, in an all-share transaction by issuing 50m shares. Oncogeni has two development programs: (1) MK cells, a new class of cellular medicine engineered to kill cancer both directly and by enhancing the activity of natural killer cells; (2) novel siRNAs (small interfering RNA) inhibit STAT-6 to kill solid tumours.

The enlarged company will welcome Nobel Laureate Prof. Sir Martin Evans as Group Chief Scientific Officer. Moreover, the skillsets of the Oncogeni team in later stage clinic trials and preparation for regulatory approval are complementary to Lyramid's knowhow in discovery and translation. Access to Oncogeni's biomedical lab in Stratford-upon-Avon will be included in the acquisition.

Investment thesis: Roquefort believes that its MDK pre-clinical programs are the most advanced in the industry and the enlarged company will have four best-in-class oncology drug development programs. Management is targeting clinical readiness for one of its development programs by the end of 2023.

As the global burden of cancer care continues to increase, quality cancer assets remain a seller's market. Data from BioSciDB for 2016-1H21 suggests that oncology licensing partnerships typically bring in double-digit upfront payments and some phase 1 programs attract over $100m in upfronts in 2020 and 1H21. Good safety results and efficacy results, patent applications and awards, IND/CTA filings and minimum "white space" between clinical phases will be the key indicators to Roquefort's quality and progress of its drug development programs.

Table of Contents

Corporate structure

Roquefort Therapeutics was incorporated in the UK as a special purpose acquisition company (SPAC) in August 2020 to acquire businesses in drug discovery and development. The Company was admitted to trading on the London Stock Exchange's Standard List of the Main Market in March 2021 and raised £1m at a price of 5p per share.

In December 2021, Roquefort acquired 100% of Lyramid, the owner of two MDK drug development programs and the exclusive licensee of the world's largest portfolio of patents on MDK from Anagenics. Currently, Roquefort is in the process of acquiring Oncogeni for MK cell therapy and siRNA targeting novel STAT-6 target in solid tumours.

High-level corporate structure (after Oncogeni acquisition)



Source: Company Data

With the acquisition of Oncogeni, Roquefort will have a highly complementary portfolio of four best-in-class medicines focused on the cancers resistant to existing therapies: (1) MDK antibodies with significant in vivo efficacy and completed toxicity tests with primates and rodents; (2) MDK RNA therapeutics with novel anti-cancer gene editing action; (3) MK cell therapy with direct and nature-killer-mediated anti-cancer action; and (4) siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.

About MK cells

MK cells are a novel engineered cell type invented by Nobel Laureate, Prof. Sir Martin Evans' team, to kill cancer directly, attract NK cells and to activate (prime) natural killer cells to kill cancer. MK cells are designed to be well tolerated, to avoid the risk of serious side effects associated with CAR-T (Chimeric antigen receptor-T cell) therapy. CAR T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. In vitro results for MK cell type #2 and #4 show priming of natural killer cells and direct cytotoxicity in leukaemia and myeloma cancers.

About STAT-6 siRNA

siRNA (small interfering RNA) targets STAT-6, a novel cancer target that is prevalent in cancers with high mortality. STAT-6 is an intracellular target, which is not druggable with conventional medicines and which is implicated in cancer development, progression, metastasis, and resistance to treatment. siRNA inhibits STAT6 in order to drive cancer cell death and slow cancer cell growth. Oncogeni's studies on siRNA showed significant anti-cancer activity (*$p<0.05$) in vivo in validated animal models.

About Oncogeni

Oncogeni was spun-out from Celixir PLC in 2019. Professor Sir Martin Evans is a co-founder of Celixir and will be joining Roquefort as an Executive Director on a part-time basis after its acquisition of Oncogeni.

Among Oncogeni's shareholders are Daiichi Sankyo from Japan and CH Health, a VC firm based in Israel.

Midkine: the antibody program and the RNA approach

About Midkine (MDK)

Midkine, a heparin-binding protein, has long been known to be important in embryonic development. While barely detectable in healthy adults, Midkine is highly expressed during oncogenesis. MDK hinders the normal immune response to tumours and promotes metastatic spread to other organs, thereby contributing to various levels of cancer progression and reduced patient survival.

Roquefort believes its knowhow and patent strategy (the combination of the exclusive license and the efforts to patent in-house R&D) have established the entry barrier in targeting MDK. The patent strategy is focused on both the composition of matter patents and method patents for antibodies, RNA approach and truncated MDK (multiple sequences).

Management also believes that the team is one year ahead of the game in the pre-clinical stage of developing reagents targeting the growth factor MDK for treatment of cancer.

MDK Antibody program

Roquefort has developed two MDK antibodies with high specificity for tumours. Single dose safety and PK (pharmacokinetic) studies in both rodents and primates have been completed with no significant safety concerns evident. The in-vivo efficacy results of murine antibodies are strong. Roquefort has humanised these antibodies and is currently conducting efficacy studies. Assuming strong efficacy results in 1H 2023, Roquefort hopes to conduct clinical trials on advanced cancer patients with distal metastases, which refers to cancer that has spread from the original (primary) tumour to distant organs or distant lymph nodes.

The MDK antibody program is close to the GMP (good manufacturing practice) process. Roquefort has established a good understanding of COGS (the cost of goods sold) and believes it would be easy to scale up.

RNA program with oligonucleotides

Roquefort believes that the RNA approach is highly complementary to antibodies to create an anti-cancer MDK portfolio.

Roquefort is developing antisense oligonucleotide drugs targeting MDK. Oligonucleotide (with short RNAs) changes and blocks the expression of MDK. Roquefort's lead oligonucleotide drug candidates can significantly reduce MDK mRNA levels. The lead compounds were synthesised in preparation for in vitro

experiments to test efficacy in altering cancer cell properties. Truncated MDK has shown efficacy in the validated animal model.

On 7 June 2022, Roquefort reported that its collaborative cancer research project with Professor Steve Wilton and his colleagues at Murdoch University in Perth, Australia had demonstrated >90% efficacy at the mRNA level.

The in vitro experiments have been completed with Roquefort's proprietary oligonucleotides successfully reducing high MDK levels in cancer cells by generating a truncated form of the MDK protein. The switch to the truncated MDK is consistent with the >90% efficacy at the mRNA level mentioned above. These positive results demonstrate the pre-clinical proof of principle in cancer for the antisense oligonucleotide drug development program.

Roquefort has recently updated its filed patent in Australia and has also filed a UK patent to protect the composition of the truncated MDK, mRNAs and antisense oligonucleotides.

In March 2022, Roquefort announced that it had filed its first composition of matter patent application, covering antisense oligonucleotide drugs to block the action of MDK. This patent aims to protect the IP and the potential value of this new class of RNA therapeutic drug. Provisional composition of matter patents acts as an umbrella patent, providing broad IP protection for the development of MDK-based drugs. Subsequent methods patents will later be filed to provide additional IP protections, such as covering the use of the MDK antisense oligonucleotides in different clinical indications.

Roquefort files patent applications in Australia and in the UK and then follows the PCT (Patent Cooperation Treaty) and Patent Prosecution Highway regimes. Through this process Roquefort aims to file the PCT and US patents and then in Japan, China and other major jurisdictions as the examinations are demanded. Roquefort focuses on composition of matter patents, which are considered most critical in BioPharma.

Patent licensing agreement with Anagenics

MDK was discovered by Professors Takashi Muramatsu and Kenji Kadomatsu at Nagoya University, Japan in 1988. The intellectual property associated with the discovery was acquired in 2001 by Cell Signals Inc., a Japanese biotech company. In 2008, Anagenics acquired all of the intellectual property pertaining to MDK from Cell Signals Inc. for a consideration of A$3.5m. Anagenics has since, through its own research programs and with collaborators, developed a patent portfolio and knowledge base around MDK, its inhibitors and its potential to be targeted for a number of therapeutic indications.

In 2016, Anagenics set up Lyramid as a 100%-owned subsidiary to commercialise the intellectual property owned by Anagenics, around MDK as the novel therapeutic target. In April 2021, Anagenics sold Lyramid to Provelmare Holding SA. In December 2021, Roquefort completed the acquisition of Lyramid for an initial consideration of a cash payment of £0.6m and the issue of 5m ordinary shares at an issue price of £0.10 per share. The subsequent consideration depends on Roquefort's market capitalisation on the fifth anniversary of the admission of the enlarged share capital, comprising 71.9m ordinary shares, on 21 December 2021. If Roquefort's market capitalisation exceeds £25m for five or more consecutive trading days, it shall issue 5m ordinary shares to Provelmare Holding. If Roquefort's market capitalisation exceeds £50m for five or more consecutive trading days, it shall issue a further 5m ordinary shares to Provelmare Holding.

Lyramid has an exclusive global licence with Anagenics for composition of matter and methods patents around Midkine with nine patent families comprising 37 registered patents and one application at PCT stage. In the contract entered into in August 2020, Anagenics grants a worldwide, exclusive, irrevocable royalty-bearing licence to Lyramid of the entire right, title, and interest in and to certain patent rights and confidential information known to Anagenics relating to, amongst others, the subject matter claimed in the patent rights (knowhow) in all fields and for all applications, with the right for Lyramid to sub-licence and exploit inventions.

Anagenics is entitled to receive licence fees equal to 4% of net sales of products sold by or on behalf of Lyramid and its affiliates and 8% of any sublicensing revenue.

The licence agreement shall continue in force for five years after all patent rights expire and all knowhow ceases to be confidential information, unless terminated earlier. Anagenics is entitled to terminate the agreement if Lyramid has not, on or before the fifth anniversary of 1 August 2025, commenced good manufacturing practice or administered the first dose in a phase 0 or phase 1 human clinical trial of a lead drug candidate covered by the patent rights or knowhow. The licence

agreement is not otherwise capable of termination by either party for breach or otherwise.

The license was valued at £1.2m as at 31 December 2021, to be amortised over four years starting in 2022.

Trends in licensing deals of oncology assets

Given the pre-revenue stage of Roquefort and the monetisation via licensing deals with biotech/pharma partners, we think a summary of the trends in licensing deals and valuations of oncology assets will be helpful to investors.

Increasing global cancer burden and spending

The global burden of cancer care is increasing due to longer life expectancies because incidence rates are the highest amongst older people. Before COVID-19 disruption, Cancer Research UK data suggests that 36% of new cases were in people aged 75 and over in the UK in the period 2016-2018.

According to the forecast in July 2022 by the oncology advisory firm Torreya, the global sales of innovative oncology pharmaceuticals among top 50 marketers will grow at a CAGR of 8.2% from $190bn in 2020 to $252bn in 2025.

It is hardly surprising that oncology is the leading therapy area for innovation - in terms of the level of clinical trial activity and the investments on therapeutics pipelines. Data from BioSciDB indicates that the aggregate amount of licensing upfronts in the biopharma industry in the period 2016-1H21 was $54.1bn. Of this, $23.1bn or 60% went to cancer related programs, $8.6bn or 22% to orphan diseases, $3.0bn or 7% to central nervous system diseases, $2.4bn or 6% to infectious-viral diseases, $2.0bn or 5% to autoimmune/inflammatory diseases.

Therapy areas by licensing upfront fees in 2016-1H21



Source: BioSci DB

Early-stage licensing deals and upfronts

Against this backdrop is a growing appetite for in-licensing early into oncology drug discovery and technology platforms. Torreya data indicates that the total number of oncology deals with $3mm or more upfront and global/US rights involved was 21 in 2015, 28 in 2016, 17 in 2017, 24 in 2018, 24 in 2019, peaking at 53 in 2020, 36 in 2021 and 26 in 1H22. Of this, the percentage of deals in the pre-clinical and Phase 1 stages has increased from 62.9% in 2015-2018 to 84.7% in 2021 and 1H22.

As pharmas look to gain access to novel therapeutic targets and platforms, the market for cancer assets is a seller's market, evidenced also by the higher amount of licensing upfronts since 2016. According to BioSciDB, most cancer licensing upfronts are in double-digit US$ millions and some phase 1 programs brought in over $100m in upfronts in 2020 and 1H 2021.

Mean cancer-focused licensing upfronts ($m)



Upfront cost (in $m) of buying cancer asset



Source: BioSci DB
Note: Upfront costs refer only to initial fees.

Competition in pre-clinical MDK programs

To the best of Roquefort's knowledge and as far as we are aware, there are no MDK related drugs or therapeutics for cancer on the market or in the clinical stage. Our search on ClinicalTrials.gov on 6 September found only six clinical trials worldwide in relation to MDK but none related to drug development or targeting MDK.

MDK-related trial search results on ClinicalTrials.Gov (6 September 2022)

Row	Saved	Status	Study Title	Conditions	Interventions	Locations
1	☐	Unknown †	Long Non Coding RNA HOTAIR and **Midkine** as Biomarkers in Thyroid Cancer	• Thyroid Cancer	• Other: complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction	
2	☐	Unknown †	The Role of **Midkine** in Diagnosis of Thyroid Cancer	• Thyroid Cancer		
3	☐	Completed	**Midkine** and ACE-Ang II Induced Endothelial Injury in Sepsis	• Sepsis		• Department of Critical Care Medicine Nanjing, Jiangsu, China
4	☐	Completed	Relation Between Cachexia, Diabetes and periNeural Invasion in PANcreatic Cancer- Biomarkers Substudy	• Pancreatic Cancer, Adult • Cachexia • Pain • Diabetes Mellitus	• Diagnostic Test: Point-of care biomarkers • Other: Clinical, venous blood samples, pancreatic tissue • Other: Follow-up	• Regional Institute of Gastroenterology and Hepatology Cluj Napoca, Cluj, Romania
5	☐	Not yet recruiting	TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma	• Glioblastoma	• Drug: TN-TC11G • Drug: Temozolomide Oral Product • Radiation: Radiotherapy	• Institut Català d'Oncología L'Hospitalet L'Hospitalet de Llobregat, Barcelona, Spain • Hospital Universitario Son Espases Palma de Mallorca, Mallorca, Spain • Consorcio Hospitalario Provincial de Castellón Castelló, Valencia, Spain • (and 5 more...)
6	☐	Unknown †	Effect of ACE Genotype on Cardiovascular Rehabilitation	• Cardiovascular Disease	• Behavioral: concentric cardiovascular training • Behavioral: eccentric cardiovascular training • Genetic: ACE genotyping	• Balgrist University Hospital Zurich, Switzerland • University Hospital Zurich Zurich, Switzerland

Source: ClinicalTrials.Gov website run by U.S. National Library of Medicine
Note: "Unknown" indicates that the study has passed its completion date and status has not been verified in more than two years.

We also ran online searches on all the MDK patent owners and only found one pre-clinical trial by RIBOMIC Inc. for osteosclerosis.

Risks

We think the biggest risks for Roquefort's MDK programs are perhaps whether the development team can hit the milestones in the licensing agreement on or before the fifth anniversary of 1 August 2025.

Anagenics (formerly Cellmid) acquired all the intellectual properties pertaining to Midkine in 2008 and had worked on drug/therapeutics development since then but failed to commercialise any of its pipeline.

Back in 2014, Anagenics completed several cancer xenograft efficacy and mechanism of action studies using its lead anti-Midkine antibody, showing reduced tumour growth and spread and anti-angiogenic mechanism of action.

Anagenics developed CAB 102, a humanised monoclonal antibody for use in solid tumors; CAB101, a monoclonal antibody for the treatment of kidney injury, and inflammatory and fibrotic diseases; and CMK103, a recombinant human form of MK protein for use in cardiac ischemia.

It is possible that Anagenics' focus on health and beauty products and clinically validated anti-aging solutions undermined management attention to drug development and contributed to its failure in MDK commercialisation.

Roquefort's capitalisation and ownership

Capitalisation

The Company's issued share capital consists of 71.9m ordinary shares of one penny par value as of 9 September 2022.

Roquefort was incorporated in August 2020 as a special purpose acquisition company (SPAC) by Mr Stephen West, Founder and Executive Chairman and the founding shareholders including Mr Glenn Whiddon. In March 2021, Roquefort was admitted to trading on the London Stock Exchange's Standard List of the Main Market and raised £1m at a price of 5p per share to search for acquisition targets in drug discovery and development.

Roquefort's capitalisation to date (as of September 2022)

Equity raised	Use of proceeds	Issue price	Shares issued	Post-placing shares	Time
£50k	Incorporation	1p	5m	5.0m	Aug 2020
£74k	Corporate purposes	1p	7.4m	12.4m	Nov 2020
£1m	IPO and acquisition search	5p	20m	32.4m	Mar 2021
Equity raised	Exercise of warrants	Exercise price	Shares issued	Post-exercise shares	Time
£15k	1.5m brokers warrants	1p	1.5m	33.9m	May 2021
Equity raised	Use of proceeds	Issue price	Shares issued	Post-placing shares	Time
£150k	Corporate purposes	5p	3m	36.9m	Aug 2021
£0	Consideration shares	-	5m	41.9m	Dec 2021
£3m	Corporate purposes	10p	30m	71.9m	Dec 2021

Source: Company Data

Roquefort has raised £4.289m to date, primarily £1m in the IPO mentioned above and £3m raised for the corporate activities in conjunction with the acquisition of Lyramid in December 2021.

For the acquisition of Lyramid, Roquefort paid £0.6m in cash and issued 5m shares as the initial consideration. The cash paid and the shares issued were recognised as a cash outflow of £1.1m in total for the year ended 31 December 2021.

As of June 2022, Roquefort had £2.49m of available cash.

Outstanding warrants

As of 31 December 2021, 35.875m warrants were granted and 1.5m broker warrants were exercised in April 2021.

As of 31 December 2021, Roquefort had a total of 34.375m warrants outstanding, the majority of which issued in conjunction with the two placings, one in March 2021 and the other for the placing in December 2021. The average exercise price is 10.5p.

In June 2022, Roquefort issued a total of 900,000 warrants to the two Non-Executive Directors Ms Jean Duvall and Dr Simon Sinclair, and Board Advisor Prof. Trevor Jones appointed earlier during the year. The warrants have a term of 5 years and are exercisable at a price of 15p, with 50% exercisable after 12 months and the balance exercise after 24 months.

Management and director shareholdings and warrants (as of September 2022)

Name	Position	Appointed	Ordinary shares	Warrants
Stephen West	Executive Chairman	Aug 2020	5,049,123	7,500,000
Dr Michael Stein	Non-Executive Director	Mar 2021	-	2,000,000
Dr Graham Robertson	Chief Scientific Officer	*	-	2,000,000
Mark Freeman	Non-Executive Director	Oct 2021	-	500,000
Jean Duvall	Non-Executive Director	Apr 2022	-	300,000
Dr Simon Sinclair	Non-Executive Director	Apr 2022	-	300,000
Prof. Trevor Jones	Board Advisor	Feb 2022	-	300,000
Maria Halasz	Strategic Advisor	*	-	250,000
TOTAL			5,049,123	13,150,000

Source: Company Data
*Dr Graham Robertson and Maria Halasz joined in conjunction with the acquisition of Lyramid.

Roquefort's outstanding warrants (as of December 2021)

Series	Exercise price	Expiry date	No. of warrants
Founder	£0.10	22 Mar 2026	5,000,000
Seed	£0.10	22 Mar 2026	7,000,000
New Directors	£0.05	22 Mar 2026	750,000
New Directors	£0.10	22 Mar 2026	750,000
Broker placing	£0.05	22 Mar 2024	480,000
Placing	£0.10	22 Mar 2023	10,000,000
New placing	£0.10	22 Mar 2023	1,500,000
Completion	£0.10	21 Dec 2024	3,000,000
Senior management	£0.15	21 Dec 2026	4,500,000
Optiva (advisor)	£0.10	21 Dec 2024	1,320,000
Orana (advisor)	£0.10	21 Dec 2024	175,000
Average exercise price	£0.105	TOTAL	34,375,000

Source: Company Data

Free float and major shareholders

The major shareholders are currently J Whiddon, the spouse of a former Roquefort non-executive director Glenn Whiddon (10.15%); Abdelatif Lachab (10.00%); Executive Chairman Stephen West (7.02%); Provelmare Holdings, a Panama-based company and the former owner of Lyramid (6.90%); Mark Rollins, a former Roquefort non-executive director (5.56%) and Sebastian Marr (3.34%).

We estimate Roquefort's free float to be around 52%.

Board and Management Team

Executive Chairman and Founder, Mr Stephen West, is overseeing the financial and commercial activities of the Company. With the planned acquisition of Oncogeni, Mr Ajan Reginald will join as Chief Executive Officer on a full-time basis and will also serve as an Executive Director.

Stephen West
Executive Chairman & Founder

Over 30 years' financial and corporate experience gained in public practice, oil and gas, mining and investment banking spanning Australia, UK, Europe, CIS, and Africa. Track record in growing companies

Fellow Chartered Accountant in Australia and the UK

Bachelor of Commerce (Accounting and Business Law)

Ajan Reginald
Chief Executive Officer

20 years in biopharma as a biotech CEO and senior executives at Roche (Global Head) and recently Novacyt (COO & CTO)

Track record of discovering and developing new medicines and diagnostics and value creation

MSc, University of Oxford; AMP, Harvard Business School
Kellogg MBA (Fulbright scholar)

Dr Graham Robertson, Chief Scientific Officer – Australia, is in charge of MDK drug development programs. After the planned acquisition of Oncogeni, Prof. Sir Martin Evans will assume the role as Chief Scientific Officer and Prof. Armand Keating will serve as Chief Medical Advisor.

Dr Graham Robertson
Chief Scientific Officer - Australia

Over 40 years research in areas relevant for developing drugs targeting Midkine, e.g., molecular and systems biology; chronic inflammatory processes; complex multi-organ pathology; and clinical biomarker studies

PhD in molecular virology from Macquarie University
Post-Doctoral training in gene regulation and nuclear architecture at Oxford

Prof. Sir Martin Evans
Group Chief Scientific Officer

2007 Nobel laureate in Physiology or Medicine
Winner of Copley Medal and Royal Society & Gold Medal

Ground-breaking research in embryonic stem cells and DNA recombination in mammals

2009-2017: Emeritus Professor, School of Biosciences, Cardiff University

Prof. Trevor Jones CBE FMedSci
Strategic & Scientific Advisor

Over 45 years in the pharmaceutical and biotech industry across the UK, US, and Europe. Previously as Board Director for Research & Development at The Wellcome Foundation (Wellcome plc) and Director General of the Association of the British Pharmaceutical Industry

PhD in medicine, King's College, London
Visiting professor at King's College, London

Prof. Armand Keating
Chief Medical Advisor

Distinguished physician with over 40 years' experience in cancer medicine. Former President of the American Society of Haematology

PhD and leading expert in the development of novel cancer drugs

Professor of Medicine, University of Toronto

Mr Stephen West is currently the only Executive Director. After the acquisition of Oncogeni, Professor Sir Martin Evans will join as an Executive Director on a part-time basis and Mr Ajan Reginald will join as an Executive Director on a full-time basis.

Roquefort has four Non-Executive Directors. The most recent joiners are Ms Jean Duvall, appointed on 5 April 2022, and Dr Simon Sinclair, appointed on 20 April 2022.

Dr Michael Stein
Non-Executive Director

Business leader and strategic adviser in healthcare. Founding CEO of Valo Therapeutics and also of OxStem Ltd, an award-winning biotechnology spin-out from University of Oxford

Graduated as a medical doctor and biochemist from the University of Cape Town and subsequently from the University of Oxford (Rhodes Scholar) with a doctorate in Physiological Sciences (Immunology)

Mark Freeman
Non-Executive Director

Chartered Accountant with over 25 years' experience in corporate finance and the public markets, with a focus on business development, acquisitions and mergers, project commercialisation, project development

Bachelor of Commerce, University of Western Australia

Jean Duvall
Non-Executive Director

Over 25 years' experience in executive roles in the biopharma industry. Formerly CEO & Director at Repronovo SA; Director, Executive VP & Group General Counsel at Ferring International Centre

Graduate degree from The Ohio State University and an undergraduate degree from Case Western Reserve University

Dr Simon Sinclair
Non-Executive Director

Commercial physician and scientist leader with 20 years' experience in pharma, medtech and consumer healthcare regarding translational medicine, clinical development, medical affairs, evidence-based market access, etc. Previously held senior roles at Johnson and Johnson and Merck & Co

PhD in neural transplantation from Cambridge University

Financial Statements

Income Statement (£) Y/E December	2021	Notes
Revenue	719	
Other income	130	
Cost of goods	(10,069)	
Administrative expenses	(252,392)	
Costs associated with the IPO	(182,053)	
Share based payments	(248,326)	
Costs associated with the acquisition of Lyramid	(224,744)	
Research and development expenditure	(698)	
Operating loss	(917,433)	
Finance income	-	
Profit (loss) before tax	(917,433)	To be carried forward indefinitely against future profits
Taxation	-	
Foreign exchange loss	-	
Total comprehensive income (loss)	(917,433)	Weighted average number of shares: 24,701,793
Earnings (loss) per share	(3.71)	
Balance Sheet (£) Y/E December	**2021**	**Notes**
Intangible assets	1,481,530	£1.2m: license with Anagenics
TOTAL NON-CURRENT ASSETS	1,481,530	£0.28m: deferred tax associated with license
Trade and other receivables	2,178,783	£2.1m receivable for share issue collected in Jan 2022
Cash and cash equivalents	899,721	
TOTAL CURRENT ASSETS	3,078,504	
TOTAL ASSETS	4,560,034	
Share capital	719,000	
Share premium	3,910,595	
Share based payments reserve	366,708	
Retained deficit	(914,321)	
Currency translation reserve	624	
TOTAL EQUITY	4,082,606	
Deferred tax liabilities	281,911	
TOTAL NON-CURRENT LIABILITIES	281,911	
Trade and other payables	195,517	
TOTAL CURRENT LIABILITIES	195,517	
TOTAL LIABILITIES	477,428	
TOTAL EQUITY AND LIABILITIES	4,560,034	

Source: Company Data

Cash Flow Statement (£) Y/E December	**2021**	**Notes**
Profit (loss) before tax	(996,068)	Including negative adjustment by £78,635 due to acquisition
Adjustment for:		
Foreign exchange	765	
Non-cash adjustment	(2,602)	
Share based payment	366,708	
Changes in working capital:		
Change in trade and other receivables	(2,130,636)	£2.1m: receivables related to share issue in Dec 2021
Change in trade and other payables	129,525	
Change in inventory	9,273	
CASHFLOWS FROM OPERATING ACTIVITIES	(2,623,035)	
Acquisition of subsidiary, net of cash acquired	(1,106,225)	£0.6m paid in cash; £0.5m paid in shares
CASHFLOWS FROM INVESTING ACTIVITIES	(1,106,225)	
Proceeds from issue of ordinary shares	4,789,000	
Share issuance costs	(159,405)	
CASHFLOWS FROM FINANCING ACTIVITIES	4,669,502	
Net change in cash & cash equivalents	900,335	
FX translation difference	(614)	Australia $ translated to GBP
Cash at the beginning of the period	-	
Cash at the end of the period	899,721	

Source: Company Data

Patents licensed to Lyramid

Application No.	Country	Patent/Reg. No.	Expiry Date
PCT/JP2004/002888 oligonucleotide inhibiting the expression of midkine or an antibody inhibiting the effect of midkine in prevention of intraperitoneal postoperative adhesion	France	1607102	Mar 2024
Priority: JP 2003-108428 Anti-midkine antibody for preventing post-laparotomy adhesions (Continuation of US 8,221,758)	Germany	602004050674.5	Mar 2024
	Japan	4768440	Mar 2024
	UK	1607102	Mar 2024
	US	8,221,758	Mar 2024
	US	8,748,406	Mar 2024
PCT/JP2006/322659 Method for treatment or prevention of disease associated with functional disorder of regulatory T cell	France	1964574	Nov 2026
Priority: JP 2005-329418 Method for treatment or prevention of disease associated with functional disorder of regulatory T cell	Germany	60 2006 050 228	Nov 2026
	Italy	502016000118339	Nov 2026
	Switzerland	1964574	Nov 2026
	UK	1964574	Nov 2026
	Japan	5398987	Nov 2026
	US	8,128,934	Nov 2026
PCT/JP2007/001238: Antibody recognizing C-domain of midkine	Australia	2007320657	Nov 2027
Priority: JP 2006-308466	France	2088159	Nov 2027
Antibody recognizing C-domain of midkine	Germany	2088159	Nov 2027
	Italy	2088159	Nov 2027
	Switzerland	2088159	Nov 2027
	UK	2088159	Nov 2027
	Japan	5663137	Nov 2027
	US	9,163,081	May 2031
PCT/JP2005/022354 Method to reduce loss of cardiac function following ischemia/reperfusion	US	9,023,799	Feb 2031
Priority: JP 2004-352513; JP 2005-187420 Activation of endothelial nitric oxide synthase by midkine and uses therefor in effecting vasodilation	Germany	60 2006 035 300.6	May 2026
	UK	1900380	May 2026
	US	8,288,343	Mar 2028
PCT/AU2012/000251: Antibody recognizing N-domain of midkine	France	2686016	Mar 2032

Application No.	Country	Patent/Reg. No.	Expiry Date
Priority: US 61/452,337 Antibody recognizing N-domain of midkine	Germany	2686016	Mar 2032
	Italy	2686016	Mar 2032
	Switzerland	2686016	Mar 2032
	UK	2686016	Mar 2032
	US	9,624,294	Dec 2032
PCT/AU2015/050629: Improved midkine antibody	Australia	2015333590	Oct 2035
Priority: AU 2014904102: Midkine antibody	Switzerland	3206712	Oct 2035
	Germany	3206712	Oct 2035
	UK	3206712	Oct 2035
	France	3206712	Oct 2035
	US	10,590,192	Oct 2035
Priority: AU 2018900052 Methods of treating myocarditis and/or cardiomyopathy and reagents therefor	PCT	PCT/AU2019 050706	N/A

Source: Company Data

Note: Patent names are added by Hybridan based on the application numbers disclosed.

Appendix

JUSTIA search results of Midkine related patents

The table below summarises our search results on 6 September 2022. We map our research results with those patents owned by Anagenics and licensed to Lyramid, just to give an indication of the significance of intellectual property that support Roquefort's MDK development programs. We feel this approach is complementary to the list of patents covered in the licensing agreement and summarised above, as disclosed on pages 106 and 107 of the Prospectus dated 16 December 2021, which can also be found here https://www.roquefortplc.com/category/shareholder-documents/

Blue highlights indicate the patents licensed to Lyramid

No.	Patent	Assignee	Date of patent
6572851	Method for suppressing or treating drug-induced nephropathy	Takashi Muramatsu	Jun 3, 2003
6939669	Expansion of hematopoietic cells using midkine or pleiotrophin	Meiji Dairies Corporation	Sep 6, 2005
7030099	Tumor specific promoters of the midkine gene that allow for selective expression in P53-inactivated cells	Research Corporation Technologies	Apr 18, 2006
7090983	Methods for detecting early cancer	Takashi Muramatsu	Aug 15, 2006
7241730	Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides	Universitat Zurich, Eidgenossische Technische Hochschule Zurich	Jul 10, 2007
7309695	Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA	Takashi Muramatsu	Dec 18, 2007
7390491	Agents comprising midkine or an inhibitor thereof as active ingredient	Takashi Muramatsu	Jun 24, 2008
7820160	Midkine inhibitory compositions for the treatment of angiostenosis	Medical Therapies Limited	Oct 26, 2010
7893018	Method of treatment for ischemic heart disease	Foundation for Biomedical Research and Innovation	Feb 22, 2011
7951532	Method of screening a midkine modulating agent	Children's Hospital Medical Centre	May 31, 2011
8080649	Aptamer against midkine and use thereof	Ribomic Inc.	Dec 20, 2011
8106009	Pharmaceutical composition for preventing or treating ischemic diseases	Medical Therapies Limited (former name of Cellmid)	Jan 31, 2012
8128934	Method for treatment or prevention of disease associated with functional disorder of regulatory T cell	Ribomic, Inc., Anagenics	Mar 6, 2012
8221758	Anti-midkine antibody for preventing post-laparotomy adhesions	Anagenics	Jul 17, 2012
8288343	Activation of endothelial nitric oxide synthase by midkine and uses therefor in effecting vasodilation	Nagoya University (owned by Anagenics)	Oct 16, 2012
8748406	Preventive for adhesion following abdominal surgery	Medical Therapies Limited	Jun 10, 2014
8993250	Methods and compositions for diagnosis and prognosis of renal injury and renal failure	Astute Medical, Inc.	Mar 31, 2015
9023799	Method to reduce loss of cardiac function following ischemia/reperfusion	Anagenics	May 5, 2015
9163081	Antibody recognizing C-domain of midkine	Medical Therapies Limited	Oct 20, 2015
9283300	Use of midkine protein and the protein-containing medical device	General Regenerative Ltd	Mar 15, 2016
9470695	Methods and compositions for diagnosis and prognosis of renal injury and renal failure	Astute Medical Inc.	Oct 18, 2016
9506925	Specific biomarker set for non-invasive diagnosis of liver cancer	Dragon Victory Development Ltd.	Nov 29, 2016
9506070	Aptamer against midkine and applications thereof	Ribomic Inc.; Otsuka Pharmaceutical	Nov 29, 2016
9622955	Method of treatment or prevention of hair loss or for the enhancement of hair growth	Advangen International Pty Ltd (Anagenics' 100% owned subsidiary)	Apr 18, 2017
9624294	Antibody recognizing N-domain of midkine	Anagenics	Apr 18, 2017
9658233	Assay to measure midkine or pleiotrophin level for diagnosing a growth	United States of America	May 30, 2017

Blue highlights indicate the patents licensed to Lyramid

No.	Patent	Assignee	Date of patent
9840552	Monoclonal antibody against human midkine	Nagoya University; Medical & Biological Laboratories Co., Ltd.	Dec 12, 2017
9885718	Specific biomarker set for non-invasive diagnosis of liver cancer	Dragon Victory Development Ltd.	Feb 6, 2018
10590192	Midkine antibody	Anagenics	Mar 17, 2020
10620209	Specific biomarker set for non-invasive diagnosis of liver cancer	Dragon Victory Development Ltd.	April 14, 2020
10668078	Methods and compositions for treating mesothelioma and small lung cancer that express midkine	Children's Hospital Medical Centre	Jun 2, 2020
11026950	Methods and compositions for treating mesothelioma and small lung cancer that express midkine	Children's Hospital Medical Centre	Jun 8, 2021

Source: JUSTIA, 6 September 2022

Research Disclaimer

This document should not be relied upon as being an impartial or objective assessment of the subject matter and does not constitute **investment research** for the purposes of the Conduct of Business Sourcebook (**"COBS"**) issued by the Financial Conduct Authority (**"FCA"**) to reflect the requirements of the UK retained version of Regulation 600/2014/EU (the "**MIFID II Regulation"**) and the UK retained version of Directive 2014/65/EU (the "**MIFID II Directive"**) and all rules made in connection therewith (together, known as "**MIFID II"**). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector. As a consequence, the research (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research under MIFID II; and (b) is not subject to any prohibition on dealing ahead of the dissemination of investment research (although Hybridan does impose restrictions on personal account dealing in the run up to publishing research as set out in our Conflicts of Interest Policy).

Hybridan LLP is involved in providing other financial services to the **Company which is the subject of this document ("the Company")** and, as a result, Hybridan LLP may have responsibilities to the Company which conflict with the interests of the persons who receive this document.

This document has been issued by Hybridan LLP for **information purposes only** and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity. Hybridan LLP and/or connected persons may, from time to time, effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. The information contained herein is based on materials and sources that we believe to be reliable, however, Hybridan LLP makes no representation or warranty, either express or implied, in relation to the accuracy, completeness or reliability of the information contained herein. Opinions expressed are our current opinions as of the date appearing on this material only. Any opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. None of Hybridan LLP, its affiliates or employees shall have any liability whatsoever for any indirect or consequential loss or damage arising from any use of this document.

In the United Kingdom, this report is directed at and is for distribution only to persons who (i) fall within article 19(1) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a **professional client** or **eligible counterparty** (as those terms are defined in COBS (issued by the FCA) of Hybridan LLP (all such persons together being referred to as **"relevant persons"**). This report must not be acted on or relied upon by persons in the United Kingdom who are not relevant persons.

Neither this report, nor any copy or part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this report comes should inform him or herself about and observe any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of securities laws in the United Kingdom, the United States (or any part thereof) or any other jurisdiction in any other part of the world.

Investments in general involve some degree of risk, including the risk of capital loss. The services, securities and investments discussed in this document may not be available to or suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an investment advisor. Past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested. Where investment is made in currencies other than the investor's base currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable. Levels and bases for taxation may change. When Hybridan LLP comments on AIM or NEX Exchange shares investors should be aware that because the rules for those markets are less demanding than the Official List of the London Stock Exchange the risks are higher. Furthermore, the marketability of these shares is often restricted.

Hybridan LLP and/or its associated companies may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the partners, directors, and employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives, or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is authorised and regulated by the FCA and is a member of the London Stock Exchange.

Dissemination of Research: Reports are made available to all relevant recipients at the same time. Issuers may, in certain circumstances, be permitted to review investment analysts' investment research prior to publication for review of factual accuracy only. Investment research prepared and disseminated by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is categorised as a **retail client** under COBS.

Hybridan LLP

1 Poultry, London, EC2R 8EJ

Email: research@hybridan.com

www.hybridan.com

Hybridan LLP
Research Disclosures

Investment analyst certification:

All research is issued under the regulatory oversight of Hybridan LLP. Each investment analyst of Hybridan LLP whose name appears as the author of this research hereby certifies that the opinions expressed in such research accurately reflect the investment analyst's personal and objective views about any and all of the companies or the Company discussed herein that are within such investment analyst's coverage universe.

The investment analyst who is responsible for the preparation of this research is Emily Liu, who is an employee of Hybridan.

1. Hybridan LLP may receive compensation for corporate finance services from this Company in the next twelve months.

2. Hybridan LLP acts as broker to the Company.

3. Hybridan may provide investment banking services to the Company and in that capacity may have received confidential information relevant to the securities mentioned in this research report which is not known to the researcher who has compiled this research report.

Hybridan, its partners, officers or employees or any connected persons may at the time of publication have an interest in the equity of the Company through the holding of warrants, securities, futures, options, derivatives, and any other financial instrument of any of the companies referred to in this document. Hybridan at the time of publication currently has no interest of this nature in the Company discussed herein. If exercised such interest would not be required to be notified as it would comprise less than 3% of the Company's issued share capital. Hybridan reserves the right to increase or dispose of this interest and/or the underlying shares resulting from exercise, without further notice. Any disposal or acquisition of warrants or shares will be undertaken under the FCA Disclosure Guidance and Transparency Rules Sourcebook.

No Research recommendations:

In line with our conflicts of interest policy Hybridan LLP does not produce recommendations or publish target prices on companies who are corporate clients of Hybridan LLP.

MIFID II status of Hybridan LLP research:

The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the **MIFID II Regulation**.